Hot or Nothing
See My Plan
Portrait of an elderly woman in a purple blazer with arms crossed, set against a dark background.

What Changed in the 2026 FDA Peptide Decision?

What changed in the 2026 FDA peptide decision?

Get your plan in 2 minutes

Reviewed by Taylor Anderson, RN

Aesthetic Registered Nurse

Taylor Anderson is an aesthetic registered nurse and a reviewer for Hot or Nothing.

Updated September 6, 2026

Quick answer

No, the FDA did not approve BPC-157, TB-500, KPV or related peptides in 2026. Twelve peptides left Category 2 in April and six earned advisory votes for 503A review in July, but pharmacies cannot compound them in bulk until formal rulemaking finishes.

Want your jeans to fit again? See which body options fit you and what they cost.

See My Plan
In this guide

Key takeaways

  • April removal happened because nominations were withdrawn, not as a safety clearance, and the peptides stayed off the 503A Bulks List.
  • FDA staff asked the panel to reject all seven peptides, but the panel backed six for specific uses reviewed, including ulcerative colitis, wound healing and inflammatory conditions, and voted against emideltide.
  • Legal status is unchanged since April until a final rule issues, and the July discussion and briefing papers remain on the FDA advisory calendar.

No, the FDA did not approve BPC-157, TB-500, KPV or the other peptides women ask about for skin, recovery and body shape in 2026. Effective April 23, twelve peptides left the agency's highest concern list, and on July 23 and 24 an advisory panel recommended six of them for future compounding. Those recommendations do not allow bulk compounding yet because the FDA has not completed the formal process to add them to the compounding list.

What did the FDA remove in April?

Category 2 is the FDA short list for bulk substances that raise significant safety concerns. Effective April 23, 2026, the FDA removed twelve peptides from that list, including BPC-157, KPV and TB-500, after the original nominations were withdrawn (Amanecia Health summary).

Removal took those peptides out of the highest concern group. They remained outside the 503A Bulks List, the list of bulk ingredients licensed pharmacies may use to prepare a prescription when no approved product exists, and they waited for a separate review (FDA bulk substances guide).

What did the July panel recommend, even against staff advice?

The Pharmacy Compounding Advisory Committee advises the FDA on which bulk ingredients belong on the 503A list. FDA scientists asked the panel to reject all seven peptides under review because the clinical data were limited and the drug descriptions were incomplete (Mintz review of FDA briefing papers). The panel voted the other way for six.

On July 23, BPC-157, KPV and TB-500 each received 8 yes votes, 6 no votes and 1 abstention, and MOTS-c received 7 yes votes, 5 no votes and 2 abstentions (AJMC vote report). Semax and Epitalon also received favorable votes on July 24, while emideltide, also called DSIP, failed with 6 yes votes and 7 no votes (Clinical Peptide hearing analysis). The FDA had asked the panel to weigh BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, and MOTS-c for obesity and osteoporosis (FDA meeting page).

Can pharmacies make these peptides now?

Pharmacies cannot prepare these peptides in bulk under 503A yet. Advisory votes leave the law unchanged. The FDA must decide whether to start formal rulemaking to add each substance to the 503A list, a process that often takes six to twelve months (NCPA meeting summary) (Peptide Dossier process guide).

Until the FDA issues a final rule, the peptides stay in the same legal position they held after April, out of Category 2 but outside the compounding list. You can watch the July discussion and read the briefing papers on the FDA advisory calendar while you wait for that decision.

Ready to make a move?

Answer three questions to see the treatment options that fit your goals.

See My Plan

FAQ

Did the FDA approve BPC-157, TB-500 or KPV in 2026?

No. Twelve peptides left Category 2 in April and an advisory panel recommended six for future 503A review in July, but none were approved.

What did the April 2026 FDA change do?

Effective April 23, twelve peptides left Category 2 after the original nominations were withdrawn. They stayed off the 503A Bulks List and needed separate review before bulk compounding.

What did the July 2026 advisory panel recommend?

The panel recommended BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon for the 503A list and voted against emideltide, also called DSIP. The votes are nonbinding and do not change the law.

Can a pharmacy compound these peptides now?

No. Pharmacies cannot prepare them in bulk under 503A until the FDA completes formal rulemaking to add each one, a process described as often taking six to twelve months.

Keep reading

Every body guide and treatment
Sources (6)
  1. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026 | FDA · fda.gov · captured September 6, 2026
  2. Bulk Drug Substances Nominated for Use in Compounding ... · fda.gov · captured September 6, 2026
  3. Bulk Drug Substances Used in Compounding · fda.gov · captured September 6, 2026
  4. FDA panel supports broadening access to peptides popular on the gray market · npr.org · captured September 6, 2026
  5. FDA Briefing Document Pharmacy Compounding Advisory Committee (PCAC) Meeting · fda.gov · captured September 6, 2026
  6. FDA Panel Backs 6 Peptides for Compounding | AJMC · ajmc.com · captured September 6, 2026